Product image of Leponex (Clozapine) supplied by GNH India

Leponex

Active Ingredient:
Clozapine
Origin:
EU

Leponex (Clozapine)

Clozapine, the active ingredient in Leponex, is a atypical antipsychotic presented as a tablet for oral use. It is prescribed for patients with treatment‑resistant schizophrenia and schizoaffective disorder when other antipsychotics have not provided adequate control.
GNH India supplies Leponex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Healthcare Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Leponex (clozapine) acts on dopamine and serotonin pathways to manage severe psychotic conditions.

  • Treatment‑resistant schizophrenia: reduces psychotic symptoms in patients unresponsive to other antipsychotics.
  • Schizoaffective disorder: stabilises mood and psychotic features in this mixed condition.
  • Schizophrenia (general): helps control hallucinations and delusions, especially when standard therapies fail.

How It Works

  • Clozapine antagonizes dopamine D2 receptors and serotonin 5‑HT2A receptors, while also modulating activity at other neurotransmitter sites such as muscarinic, adrenergic, and histamine receptors. This combined receptor profile leads to reduced dopaminergic transmission in mesolimbic pathways and increased serotonergic activity, contributing to its efficacy in refractory psychotic disorders.

Side Effects

Leponex may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Sedation or drowsiness
  • Constipation or gastrointestinal discomfort
  • Weight gain or increased appetite
  • Hypersalivation
  • Dizziness or orthostatic hypotension
  • Tachycardia

Serious or Rare Side Effects

  • Agranulocytosis (dangerously low white‑blood‑cell count)
  • Myocarditis or cardiomyopathy
  • Seizures, especially at higher plasma levels
  • Neuroleptic malignant syndrome
  • Severe metabolic disturbances (e.g., hyperglycaemia)
  • Life‑threatening hypotension

Precautions & Warnings

Before initiating Leponex, clinicians should consider several safety measures.

  • Blood monitoring: perform regular complete blood counts to detect agranulocytosis early.
  • Cardiovascular assessment: monitor heart rate, blood pressure, and ECG for myocarditis signs.
  • Metabolic surveillance: track weight, glucose, and lipid levels periodically.
  • CNS vigilance: assess seizure risk, especially in patients with a history of seizures.
  • Pregnancy and lactation: use only if potential benefits outweigh risks to the fetus or infant.
  • Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture.

Avoid Interactions

Leponex can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

  • Strong CYP1A2 inhibitors (e.g., fluvoxamine) can markedly increase clozapine plasma levels, raising toxicity risk.
  • Concurrent use of drugs that cause severe neutropenia (e.g., carbamazepine) may compound blood‑cell suppression.
  • Smoking cessation: abrupt nicotine withdrawal can elevate clozapine concentrations, requiring dose adjustment.

Moderate Interactions (Monitor Closely)

  • CYP1A2 inducers (e.g., rifampin) may lower clozapine levels, reducing efficacy.
  • Other anticholinergic agents can exacerbate constipation and cognitive slowing.
  • Antihypertensive medications may intensify orthostatic hypotension when combined with clozapine.

Frequently Asked Questions

Leponex contains the active ingredient clozapine and is indicated for the management of treatment‑resistant schizophrenia and schizoaffective disorder. It is prescribed when other antipsychotic therapies have not achieved sufficient control of psychotic symptoms.

Clozapine works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors while also influencing other neurotransmitter systems such as muscarinic, adrenergic, and histamine receptors. This mixed antagonism reduces dopaminergic overactivity in brain pathways linked to psychosis and improves mood regulation.

The dose of Leponex is individualized by the prescribing clinician based on the patient’s clinical response, tolerability, and laboratory monitoring. The prescriber determines the starting dose, titration schedule, and maintenance dose according to current treatment guidelines.

Clozapine is classified as pregnancy category unknown, and its safety has not been fully established. It should be used during pregnancy or lactation only when the potential benefits to the mother outweigh possible risks to the fetus or infant, and under close medical supervision.

To order Leponex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Leponex (clozapine) is an atypical antipsychotic distinguished by its efficacy in patients who do not respond to other agents. Compared with first‑generation antipsychotics, it has a lower risk of extrapyramidal symptoms but carries unique risks such as agranulocytosis, requiring regular blood monitoring.

Leponex tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Leponex is taken orally as a tablet, usually with water. The exact timing and whether it should be taken with food depend on the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without consultation.

The most serious risks of Leponex include agranulocytosis, a potentially fatal drop in white‑blood‑cell count; myocarditis or cardiomyopathy; seizures; and neuroleptic malignant syndrome. Regular laboratory monitoring and clinical assessment are essential to detect these complications early.

Leponex should be avoided in individuals with known hypersensitivity to clozapine or any component of the formulation, in patients with uncontrolled severe cardiac disease, and in those with a history of agranulocytosis from any cause. It is also contraindicated during acute infection with fever until the cause is identified.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Clozapine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT